header logo image


Page 101«..1020..100101102103..110120..»

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

July 2nd, 2024 2:42 am

$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia $8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia

Go here to see the original:
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

Read More...

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1…

July 2nd, 2024 2:42 am

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST

Read more:
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1...

Read More...

Inside information: Orion upgrades full-year outlook for 2024

July 2nd, 2024 2:42 am

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST

Read the rest here:
Inside information: Orion upgrades full-year outlook for 2024

Read More...

Foxo Technologies, Inc., Regains Compliance with SEC Reporting Requirements

July 2nd, 2024 2:42 am

MINNEAPOLIS, July 01, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced it has filed its Form 10-Q for the quarter ended March, 31, 2024 and in doing so has regained compliance with SEC reporting requirements.

Go here to read the rest:
Foxo Technologies, Inc., Regains Compliance with SEC Reporting Requirements

Read More...

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene…

July 2nd, 2024 2:42 am

SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that Rocky Mountain Cancer Centers (RMCC), part of the US Oncology Network and Sarah Cannon Research Institute (SCRI); Astera Cancer Care (ACC), a multi-specialty community oncology practice and part of the OneOncology network; and Norton Cancer Institute, are open for enrollment in the pivotal Phase 2 ALPHA3 trial.

Here is the original post:
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene...

Read More...

GRI Bio to Present at the 8th Annual IPF Summit

July 2nd, 2024 2:42 am

LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.

Read the rest here:
GRI Bio to Present at the 8th Annual IPF Summit

Read More...

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

July 2nd, 2024 2:42 am

SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024.

Read the original here:
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Read More...

Ricky Williams Applauds NCAA’s Decision to Remove Cannabinoids from Banned Substances List, Emphasizes Need for Education on Cannabis

July 2nd, 2024 2:42 am

LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Ricky Williams, former Heisman Trophy winner, renowned cannabis advocate, and founder of the cannabis brand Highsman, has expressed his strong support for the NCAA's recent decision to remove cannabinoids from its list of banned substances. This groundbreaking move marks a significant shift in the acceptance of cannabis in sports and aligns with the growing recognition of its potential benefits.

Read more here:
Ricky Williams Applauds NCAA’s Decision to Remove Cannabinoids from Banned Substances List, Emphasizes Need for Education on Cannabis

Read More...

Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research…

July 2nd, 2024 2:42 am

SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium being held June 30 to July 5, 2024 in Salamanca, Spain.

Read the original:
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research...

Read More...

TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development…

July 2nd, 2024 2:42 am

The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11%

View original post here:
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development...

Read More...

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024

July 2nd, 2024 2:42 am

PALO ALTO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for the month ended June 30, 2024 and quarter ended June 30, 2024.

See more here:
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024

Read More...

Protect Pharmaceutical Corp. Issues Corporate Update

July 2nd, 2024 2:42 am

ANKARA, Turkey, July 01, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.'s (OTC: PRTT) (“Company”) President, Ali Yildiz, provides its shareholders with the following informational update:

See more here:
Protect Pharmaceutical Corp. Issues Corporate Update

Read More...

A-S Medication Solutions Announces Strategic Transition

July 2nd, 2024 2:42 am

LIBERTYVILLE, Ill., July 01, 2024 (GLOBE NEWSWIRE) -- A-S Medication Solutions (ASM) today announced a strategic transition of its relationship with Triple Aim Consulting, LLC (“TAC”).

View original post here:
A-S Medication Solutions Announces Strategic Transition

Read More...

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

July 2nd, 2024 2:42 am

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer.

Read more:
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

Read More...

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

July 2nd, 2024 2:42 am

NEW YORK and VIENNA, July 01, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of HIV. As a result, HOOKIPA achieves a $5 million non-dilutive milestone payment under its collaboration and license agreement with Gilead.

Read the original:
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Read More...

Alvotech Issues New Shares to Holders of Convertible Bonds

July 2nd, 2024 2:42 am

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, with maturity on December 20, 2025 (the “Convertible Bonds”).

Read more:
Alvotech Issues New Shares to Holders of Convertible Bonds

Read More...

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III…

July 2nd, 2024 2:42 am

PARIS, FRANCE, 2 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today confirmation of an expanded collaboration and license agreement with Exelixis, Inc. for the development of Cabometyx® (cabozantinib) in advanced pancreatic neuroendocrine tumors (pNETs) and advanced extra-pancreatic neuroendocrine tumors (epNETs). The agreement is based on positive outcomes from the CABINET Phase III trial, led by the Alliance for Clinical Trials in Oncology and sponsored by the National Cancer Institute (NCI), which investigated Cabometyx versus placebo in people living with advanced pNETs or advanced epNETs whose disease had progressed after prior systemic therapy. An independent Data and Safety Monitoring Board recommended to stop accrual to the study, unblind patients and allow crossover from placebo to Cabometyx. This was due to early efficacy demonstrated at an interim analysis in both of the trial’s cohorts, with clinically meaningful improvements in progression-free survival (PFS).1

See the original post here:
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III...

Read More...

Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.

July 2nd, 2024 2:42 am

PRESS RELEASE – PRIVILEGED INFORMATION

View post:
Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.

Read More...

The keys to longevity may start in the lab. How aging science is … – NPR

July 2nd, 2024 2:41 am

I used to flinch at the topic of aging. Is there anything we can do about the inevitable?

But recently I've been digging into a new wave of longevity research that is making it an exciting time to be an aging human which is all of us.

It turns out, we all age at varying rates. Super-agers may have great genes, but research shows our habits and routines everything from what we eat and how we move our bodies to who we spend our time with matter a lot, when it comes to aging well.

Now, the next frontier is to target the basic biology of aging and come up with new interventions to slow it down.

Many scientists are optimistic that we're on the cusp of breakthroughs. Not only to help us live longer, but more importantly to extend the number of years we live with good health.

This is the goal of researchers at the Human Longevity Lab at the Northwestern University Feinberg School of Medicine. They're recruiting study participants so they can test what kinds of interventions may slow the rate of aging. To that end, I decided to roll up my sleeve for science.

When I arrived, the first step was a quick blood draw. The Potocsnak Longevity Institute is housed on the light-filled 21st floor of Northwestern Memorial Hospital, overlooking Lake Michigan. It felt more like a spa than a doctor's office. I didn't anticipate the vast range of data and insights scientists could glean from a battery of tests.

Over a four-hour period, they performed more than two dozen assessments. At first it felt a bit like an annual physical. They checked my blood pressure, weight, glucose and cholesterol.

NPR's Allison Aubrey has her body composition measured inside a BodPod. Several other tests performed at the longevity lab led by Dr. Douglas Vaughan are used to estimate biological age. Jane Greenhalgh/NPR hide caption

NPR's Allison Aubrey has her body composition measured inside a BodPod. Several other tests performed at the longevity lab led by Dr. Douglas Vaughan are used to estimate biological age.

But then, the tests got a lot more interesting. Inside a small exam room, a medical assistant opened the hinge of a BodPod, a capsule that looks like a submersible. The machine assessed my body composition, determining the ratio of fatty mass to lean mass, which includes muscle. Strength is a key marker of healthy aging, helping us fend off frailty and falls.

Next, I was asked to sniff and identify a range of distinct smells from leather to chocolate to test olfactory function. The loss of smell can be an early sign of disease and cognitive decline. They scanned my retina and took digital images of the inside of my eyes, which can also help detect disease. And I took a memory and cognitive function test, called MOCA. Thankfully, all was healthy.

Then I went through a slew of cardiovascular health tests. They measured my endothelial function, which keeps blood flowing smoothly through the body. They looked at my heart rate variability and pulse-wave velocity, which is an indicator of stiffness of the arteries. I had electrodes placed onto my chest for an electrocardiogram.

Midway through I was feeling a bit nervous, and my mind raced to what ifs.

Of all the tests they performed, the most intriguing is the GrimAge test. This test predicts biological age. It's gauging whether your DNA age is younger, or older, than your actual age, known as chronological age. Conjure images of the Grim Reaper? Yep, that's the idea: The test can estimate how quickly, or slowly, you're aging.

To figure this out, researchers use a technique based on DNA methylation, which is a measure of modifications in our DNA. Basically, as we age, compounds called methyl groups attach to some of our DNA molecules, which can turn genes on or off. Researchers have shown that the higher the proportion of methylated DNA in certain locations, the more accelerated a person's biological age. Published research suggests this is a reliable way to predict life span and health span.

No one wants to find out they're aging faster than their peers, right? But here's the exciting part. Our biological age may be malleable. The hope is that we can slow down our rate of aging by making changes to lifestyle. Down the line, there may be anti-aging pills or other interventions.

Dr. Douglas Vaughan and Dr. John Wilkins of the Northwestern University Feinberg School of Medicine and the Potocsnak Longevity Institute. Allison Aubrey/NPR hide caption

Dr. Douglas Vaughan and Dr. John Wilkins of the Northwestern University Feinberg School of Medicine and the Potocsnak Longevity Institute.

For researchers, the GrimAge test isn't just a way to estimate DNA age. It's a tool to study whether interventions can alter it.

"That's the big ray of optimism that comes through all of this the possibility that we can slow down aging and extend the health span of people," says Dr. Douglas Vaughan, director of the Longevity Institute. Health span is the number of years we live with good health. "It can be changed very rapidly in experimental models and probably in people, too," he says.

For example, smoking has a very strong effect on methylation. "Tens of thousands of locations gain methylation when you smoke," explains researcher Steve Horvath, who developed the epigenetic clock used as part of the GrimAge test. People with obesity also exhibit higher methylation at certain locations. "Conversely, if you eat vegetables, if you are lean, if you exercise, that slows methylation age," he explains.

Now, of course, it's long been known that smoking and eating poorly are bad for you. But researchers can now test specific interventions to see if it's possible to move the needle.

Vaughan's deep interest in aging took off when he identified a distinct genetic variant in an Amish community in Indiana. People who have the variant are protected from diabetes and have healthier cardiovascular systems compared to people who don't. In the laboratory, when Vaughan engineered mice to have only a 50% level of a protein associated with this mutation, their life spans increased by nearly fourfold. "This was a eureka moment," he says.

He tells his current medical students that in their careers they will prescribe interventions to slow down biological aging in their patients.

"I don't know exactly what that's going to be. It might be a drug. It might be a lifestyle intervention, for all I know it might be gene editing," Vaughan says. "But there are going to be ways that we are going to slow down this process and give people a longer health span."

People who live in the upscale Chicago neighborhood where the Human Longevity Lab is located can expect to live a much longer, healthier life compared to people who live just a few miles away. Vaughan wants to help close this gap.

"I'm worried about the poor soul in south Chicago who has a life expectancy of 55, compared to 92 in the neighborhood where we're standing right now," he says. A stunning difference of more than 30 years. (You can check out life expectancy in your ZIP code here.)

A lot of factors play into this life expectancy gap including poverty, housing, stress and crime, which can all work against health span.

Vaughan and his collaborators are enrolling people from a wide range of ages, ethnic groups, neighborhoods and socioeconomic status to see what works to slow biological aging for everybody.

"There are lots of people who've been dealt a bad hand with regard to aging," Vaughan says. Their goal is to find affordable, evidence-based interventions that can benefit everyone, regardless of socioeconomic status.

For example, there's interest in studying stress, which Vaughan says could be "part of the reason for the discrepancy in the life expectancy in different neighborhoods of Chicago." To study this, he could measure people's biological age at baseline, have them try a stress-reduction program, and test again to see if their results changed.

Vaughan is also interested in studying people with chronic HIV, who tend to age at an accelerated rate. A charitable gift from a Chicago family with a shared interest helped launch the institute. Vaughan's team is considering a range of interventions to test whether they can slow down aging in this population.

"It might be weight training, it might be intermittent fasting, it might be dietary manipulations, it might be drugs that are available now that might have anti-aging effects," Vaughan explains, citing the diabetes drug metformin.

Longevity and health span research is attracting lots of funding and attention, from places like the Hevolution Foundation, which provides grants and early stage investments, and Altos Labs, a biotechnology company, founded by Dr. Rick Klausner, which is investigating ways to reprogram or rejuvenate cells.

Dozens of groups have signaled their intent to compete in the $101 million X-PRIZE global competition focused on treatments that support healthy longevity everything from new drugs or supplements, to devices, to repurposing old drugs for new uses.

"Teams have to come to the starting line and we're going to set up the frameworks by which they prove their therapeutic works," says XPRIZE's Jamie Justice, who is also a researcher at Wake Forest University School of Medicine.

Fortunately, my GrimAge score came back younger than my actual age, though I did get some surprises. I learned that my body composition isn't optimal. Turns out, I need to build more lean muscle mass, which is pretty common as we age especially for women.

With muscle mass, if you don't use it, you lose it. After the age of 30 to 35, muscle starts to slowly decline. And after age 65 or so, this loss accelerates. So it's never too soon to start building a reserve. My goal for this year is to build muscle through resistance training and an optimal diet. And also, to reduce stress.

My experience in the longevity study has motivated me to get started on a new project: How To Thrive As You Age. We'll have more stories on healthy aging interventions coming soon.

As part of this project, we hope you'll share your healthy aging tips with us. What habits or lifestyle hacks have you've adopted to thrive as you age? Please use this form to share your thoughts or email us at Thrive@npr.org.

Series editors Jane Greenhalgh and Carmel Wroth

More here:
The keys to longevity may start in the lab. How aging science is ... - NPR

Read More...

The 7 Keys to Living Longer and Healthier – The New York Times

July 2nd, 2024 2:41 am

Humans have searched for the secret to immortality for thousands of years. For some people today, that quest includes things like sleeping in a hyperbaric chamber, experimenting with cryotherapy or blasting oneself with infrared light.

Most aging experts are skeptical that these actions will meaningfully extend the upper limits of the human life span. What they do believe is that by practicing a few simple behaviors, many people can live healthier for longer, reaching 80, 90 and even 100 in good physical and mental shape. The interventions just arent as exotic as transfusing yourself with a young persons blood.

People are looking for the magic pill, said Dr. Luigi Ferrucci, the scientific director of the National Institute on Aging, and the magic pill is already here.

Below are seven tips from geriatricians on how to add more good years to your life.

The number one thing experts recommended was to keep your body active. Thats because study after study has shown that exercise reduces the risk of premature death.

Physical activity keeps the heart and circulatory system healthy and provides protection against numerous chronic diseases that affect the body and mind. It also strengthens muscles, which can reduce older peoples risk of falls.

If we spend some of our adult years building up our muscle mass, our strength, our balance, our cardiovascular endurance, then as the body ages, youre starting from a stronger place for whatever is to come, said Dr. Anna Chang, a professor of medicine specializing in geriatrics at the University of California, San Francisco.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit andlog intoyour Times account, orsubscribefor all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?Log in.

Want all of The Times?Subscribe.

See more here:
The 7 Keys to Living Longer and Healthier - The New York Times

Read More...

Page 101«..1020..100101102103..110120..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick